
According to data from Benzinga Pro, during Q4, Jazz Pharmaceuticals's (NASDAQ:JAZZ) reported sales totaled $896.73 million. Despite a 33.09% increase in earnings, the company posted a loss of $35.35 million. In Q3, Jazz Pharmaceuticals brought in $838.12 million in sales but lost $52.83 million in earnings.